Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-037581

Options or other derivatives

  • Chief Development Officer acquired 120,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Yeleswaram Krishnaswamy Chief Development Officer 2026-02-02 Grant or award · Stock Option (Right to Buy) +120,000 120,000 D: show line 1 in the form
Loading xslF345X05/ownership.xml…